Markets:

Overview

News

Currencies

International

Treasuries

Soleno Therapeutics, Inc. - Common Stock (NQ:SLNO)

52.27 +12.78 (+32.38%)

Streaming Delayed Price Updated: 1:39 PM EDT, Apr 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Soleno Therapeutics, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Soleno Therapeutics Stock Slumps After Scorpion Capital Reveals Short Position: But Retail’s Not Pessimistic Yet ↗

August 15, 2025

Via Stocktwits

Soleno Under Serious Scrutiny As Short Seller Alleges PWS Drug Is Overpriced, Unsafe ↗

August 15, 2025

Children were reportedly hospitalized after starting treatment. Scorpion Capital suggests Soleno's medication could face market withdrawal.

Via Benzinga

Soleno (SLNO) Q2 Revenue Jumps 30% ↗

August 06, 2025

Via The Motley Fool

Soleno Therapeutics Inc (NASDAQ:SLNO) Reports Q2 2025 Earnings Beat with Strong VYKAT™ XR Launch Performance ↗

August 06, 2025

Soleno Therapeutics (SLNO) reported Q2 2025 revenue of $32.66M, beating estimates by 27.4%, with a narrower EPS loss. Stock rose 1.23% post-earnings amid strong VYKAT™ XR launch.

Via Chartmill

Topics Earnings

Earnings Scheduled For August 6, 2025 ↗

August 06, 2025

Via Benzinga

Soleno Therapeutics's Earnings: A Preview ↗

August 05, 2025

Via Benzinga

Earnings Scheduled For May 7, 2025 ↗

May 07, 2025

Via Benzinga

Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity ↗

July 10, 2025

Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal.

Via Investor's Business Daily

Topics Intellectual Property

Aardvark's Hunger-Suppressing Drug Promises Weight Loss Without GI Distress ↗

June 30, 2025

Aardvark's lead drug ARD-101 targets PWS and HO with trials underway and funding secured through 2027 after a $94.2 million IPO in February.

Via Benzinga

Topics Initial Public Offering

10 Health Care Stocks Whale Activity In Today's Session ↗

April 18, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

April 17, 2025

Via Benzinga

Soleno Launches Pill For Hyperphagia In Prader-Willi Syndrome Patients But Retail’s Unmoved ↗

April 14, 2025

VYKAT XR has now been delivered to the first individuals living with PWS who have been prescribed the medication, the company said.

Via Stocktwits

Tesla To $455? Here Are 10 Top Analyst Forecasts For Monday ↗

March 31, 2025

Via Benzinga

Soleno Shares Are Up Today: What's Going On? ↗

March 27, 2025

Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares are trading higher Thursday after the company announced it secured FDA approval for its first commercial drug, Vykat XR (diazoxide choline)...

Via Benzinga

Top stock movements in today's session. ↗

March 27, 2025

Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

March 27, 2025

Via Benzinga

Which stocks are gapping on Thursday? ↗

March 27, 2025

The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session.

Via Chartmill

Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results ↗

March 27, 2025

Via Benzinga

Top movers in Thursday's pre-market session ↗

March 27, 2025

Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Via Chartmill

Concentrix Posts Better-Than-Expected Earnings, Joins Soleno Therapeutics, Petco Health and Wellness, MillerKnoll And Other Big Stocks Moving Higher On Thursday ↗

March 27, 2025

Via Benzinga

Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, Pulling Aardvark Higher ↗

March 27, 2025

The drug treats excessive hunger that often leads to obesity in patients with a rare, genetic disease.

Via Investor's Business Daily

Behind the Scenes of Soleno Therapeutics's Latest Options Trends ↗

March 27, 2025

Via Benzinga

Soleno Therapeutics Stock Rockets 34% Pre-Market After FDA Approves Prader-Willi Syndrome Drug: Retail Sentiment Peaks ↗

March 27, 2025

The company expects the drug, the first approved therapy to address hyperphagia in PWS patients, to be available in the U.S. starting April 2025.

Via Stocktwits

Soleno Therapeutics Secures FDA Approval For Its First Commercial Drug For Rare Genetic Disorder ↗

March 27, 2025

Soleno's Vykat XR wins FDA approval as the first treatment for hyperphagia in Prader-Willi syndrome, with U.S. availability expected by April 2025.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

March 27, 2025

Via Benzinga

US Stocks Likely To Open Mixed: 'Expect Volatility. Buckle Up,' Says Expert ↗

March 27, 2025

U.S. stock futures were swinging between gains and losses on Thursday after snapping a three-day winning streak on Wednesday. Futures of major benchmark indices were mixed in premarket trading. Aiming...

Via Benzinga

Topics Supply Chain World Trade

Why Greenland Technologies Shares Are Trading Higher By Around 89%; Here Are 20 Stocks Moving Premarket ↗

March 27, 2025

Via Benzinga

Why Soleno Therapeutics Stock Blasted 9% Higher Today ↗

October 08, 2024

The company's Prader-Willi treatment inched closer to FDA approval.

Via The Motley Fool

PepsiCo, DocuSign, Robinhood And Other Big Stocks Moving Higher On Tuesday ↗

October 08, 2024

Via Benzinga

Hain Celestial Posts Upbeat Q4 Earnings, Joins Soleno Therapeutics, Energizer Holdings And Other Big Stocks Moving Higher On Tuesday ↗

August 27, 2024

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.